Neurosense Therapeutics Valuation
| NRSN Stock | USD 1.05 0.00 0.00% |
Today, the firm appears to be undervalued. Neurosense Therapeutics secures a last-minute Real Value of $3.61 per share. The latest price of the firm is $1.05. Our model forecasts the value of Neurosense Therapeutics from analyzing the firm fundamentals such as Shares Owned By Insiders of 25.55 %, return on equity of -24.78, and Current Valuation of 31.13 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Neurosense Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Neurosense Therapeutics is based on 3 months time horizon. Increasing Neurosense Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Neurosense Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neurosense Stock. However, Neurosense Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.05 | Real 3.61 | Target 11.5 | Hype 1.06 |
The intrinsic value of Neurosense Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Neurosense Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Neurosense Therapeutics helps investors to forecast how Neurosense stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neurosense Therapeutics more accurately as focusing exclusively on Neurosense Therapeutics' fundamentals will not take into account other important factors: Neurosense Therapeutics Cash |
|
Neurosense Therapeutics Total Value Analysis
Neurosense Therapeutics is now projected to have valuation of 31.13 M with market capitalization of 27.11 M, debt of 73 K, and cash on hands of 10.37 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Neurosense Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
31.13 M | 27.11 M | 73 K | 10.37 M |
Neurosense Therapeutics Asset Utilization
One of the ways to look at asset utilization of Neurosense is to check how much profit was generated for every dollar of assets it reports. Neurosense Therapeutics secures a negative usage of assets of -3.04 %, losing $0.0304 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Neurosense Therapeutics shows how discouraging it operates for each dollar spent on its assets.Neurosense Therapeutics Profitability Analysis
Based on Neurosense Therapeutics' profitability indicators, Neurosense Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Neurosense Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -2.4 M | Current Value -2.4 M | Quarterly Volatility 1.6 M |
For Neurosense Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neurosense Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neurosense Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neurosense Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neurosense Therapeutics over time as well as its relative position and ranking within its peers.
Neurosense Therapeutics Earnings per Share Projection vs Actual
By analyzing Neurosense Therapeutics' earnings estimates, investors can diagnose different trends across Neurosense Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Neurosense Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Neurosense Therapeutics Ownership Allocation
Neurosense Therapeutics maintains a total of 29.55 Million outstanding shares. Neurosense Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Neurosense Therapeutics Profitability Analysis
Net Loss for the year was (10.21 M) with profit before overhead, payroll, taxes, and interest of 0.About Neurosense Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Neurosense Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Neurosense Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Neurosense Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Neurosense Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Neurosense Therapeutics. We calculate exposure to Neurosense Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neurosense Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -19.8 K | -20.8 K |
Neurosense Therapeutics Current Valuation Indicators
Neurosense Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Neurosense Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Neurosense Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Neurosense Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Neurosense Therapeutics' worth.When determining whether Neurosense Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurosense Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurosense Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurosense Therapeutics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could Neurosense diversify its offerings? Factors like these will boost the valuation of Neurosense Therapeutics. Anticipated expansion of Neurosense directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurosense Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Neurosense Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Neurosense Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Neurosense Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Neurosense Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurosense Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Neurosense Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.